Day One Biopharmaceuticals (NASDAQ:DAWN – Get Rating)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $45.00 target price on the stock. HC Wainwright's target price would suggest a potential upside of 132.56% from the stock's previous close.
Other analysts also recently issued research reports about the company. The Goldman Sachs Group lifted their price target on Day One Biopharmaceuticals from $45.00 to $62.00 and gave the company a "buy" rating in a research note on Monday, January 9th. Piper Sandler boosted their price target on Day One Biopharmaceuticals from $40.00 to $45.00 and gave the stock an "overweight" rating in a research report on Sunday, January 8th. Needham & Company LLC reissued a "buy" rating and set a $48.00 price target on shares of Day One Biopharmaceuticals in a research report on Tuesday. Bank of America began coverage on Day One Biopharmaceuticals in a report on Thursday, December 1st. They set a "buy" rating and a $34.00 price objective for the company. Finally, Capital One Financial began coverage on Day One Biopharmaceuticals in a report on Wednesday, February 8th. They set an "overweight" rating and a $40.00 price objective for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $44.14.
Get
Day One Biopharmaceuticals alerts:
Day One Biopharmaceuticals Trading Down 1.9 %
DAWN stock opened at $19.35 on Tuesday. The business's 50-day moving average price is $20.78 and its two-hundred day moving average price is $20.98. The firm has a market cap of $1.42 billion, a PE ratio of -8.92 and a beta of -1.94. Day One Biopharmaceuticals has a 1-year low of $5.44 and a 1-year high of $28.35.
Insider Activity at Day One Biopharmaceuticals
In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 10,000 shares of the company's stock in a transaction on Tuesday, December 20th. The stock was sold at an average price of $20.07, for a total transaction of $200,700.00. Following the completion of the sale, the chief financial officer now directly owns 276,497 shares in the company, valued at $5,549,294.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Jeremy Bender sold 12,500 shares of the company's stock in a transaction that occurred on Wednesday, December 21st. The stock was sold at an average price of $20.32, for a total value of $254,000.00. Following the sale, the chief executive officer now directly owns 1,192,424 shares in the company, valued at $24,230,055.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Charles N. York II sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, December 20th. The stock was sold at an average price of $20.07, for a total transaction of $200,700.00. Following the transaction, the chief financial officer now owns 276,497 shares of the company's stock, valued at approximately $5,549,294.79. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 107,126 shares of company stock worth $2,243,406. Company insiders own 8.70% of the company's stock.
Institutional Investors Weigh In On Day One Biopharmaceuticals
A number of institutional investors have recently modified their holdings of DAWN. Quantbot Technologies LP acquired a new position in Day One Biopharmaceuticals in the second quarter valued at $51,000. Amalgamated Bank lifted its stake in shares of Day One Biopharmaceuticals by 21.0% in the 3rd quarter. Amalgamated Bank now owns 3,577 shares of the company's stock valued at $72,000 after purchasing an additional 620 shares during the period. UBS Group AG acquired a new position in shares of Day One Biopharmaceuticals in the 2nd quarter valued at about $69,000. SG Americas Securities LLC bought a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter valued at about $169,000. Finally, AQR Capital Management LLC acquired a new stake in Day One Biopharmaceuticals during the fourth quarter worth approximately $205,000. 86.08% of the stock is owned by institutional investors.
About Day One Biopharmaceuticals
(Get Rating)
Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.
See Also
- Get a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey's General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for Day One Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Day One Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
